Pulmonary safety of ophthalmic beta‐blockers: a nationwide registry‐based cohort study

Kristensen, Mathias L.; Simonsen, Jan Henrik; Torp‐Pedersen, Christian; Vorum, Henrik; Aasbjerg, Kristian

doi:10.1111/aos.13663

Cited by 1 publication

(1 citation statement)

References 20 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28] A recent populationbased study of almost 100,000 patients newly prescribed IOP lowering treatment found that patients using medication for pulmonary disease had a significantly higher chance of stopping beta-blockers within 90 days of commencement compared to those without pulmonary disease (8% vs. 4%). [32] The rate of discontinuation of other IOP lowering medications was similar regardless of whether the patient had asthma or COPD.…”

Section: Pulmonary Safetymentioning

confidence: 86%

40 years of topical beta-blockers for glaucoma

Lee¹,

Tatham²

2018

cleverjournal

View full text Add to dashboard Cite

The introduction of topical beta-blockers in 1978 was a major breakthrough in the treatment of ocular hypertension and glaucoma, and although no longer first-line, betablockers remain a commonly prescribed and important intraocular pressure (IOP) lowering medication. On the 40 th anniversary of their introduction we critique the current role of topical beta-blockers, with particular regard to their efficacy, side effects, and role in fixed-dose combinations. While beta-blockers are effective at lowering IOP during the day, sleep laboratory studies have shown that they have minimal effect overnight, likely due to the physiological nocturnal reduction in aqueous production. Cardiac and respiratory side effects are especially important to consider in elderly patients with multiple comorbidities or in those using multiple systemic medications, which may affect beta-blocker metabolism. The increasing number of alternative medical and minimally invasive surgical options for glaucoma treatment is likely to see a reduction in beta-blocker prescribing.

show abstract

Section: Pulmonary Safetymentioning

confidence: 86%